MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Amicus Therapeutics Company Profile (NASDAQ:FOLD)

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 2 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $12.88 (137.11% upside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016Leerink SwannReiterated RatingOutperform$17.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Bank of AmericaInitiated CoverageBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016Robert W. BairdInitiated CoverageNeutral$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Chardan CapitalBoost Price TargetBuy$10.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman SachsInitiated CoverageNeutral$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Cowen and CompanyReiterated RatingOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016JPMorgan Chase & Co.Reiterated RatingBuy$18.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2015B. RileyBoost Price TargetBuy$14.00 -> $17.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Amicus Therapeutics (NASDAQ:FOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2016Q4($0.31)($1.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.24)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.21)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2015Q414($0.18)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.21)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014($0.23)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014($0.24)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q4 13($0.32)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q3($0.32)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Amicus Therapeutics (NASDAQ:FOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
DateHeadline
06/29/16 05:22 AMAmicus Therapeutics, Inc. on Focus After Raising In Today's Session - Press Telegraph
06/28/16 08:55 AMCovering the Bases on Amicus Therapeutics, Inc. (NASDAQ:FOLD): Where is the Stock Going? - Press Telegraph
06/27/16 03:58 PMToday's Hot List: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Barrick Gold Corporation (NYSE:ABX), Lennar ... - KC Register
06/27/16 08:30 AMAmicus Therapeutics Incorporated (NASDAQ:FOLD) Short Interest Increased By 2.15% - Engelwood Daily
06/27/16 08:30 AMNext Weeks Broker Price Targets For Amicus Therapeutics, Inc. (FOLD) - Fiscal Standard
06/23/16 03:12 PMAmicus Therapeutics (NASDAQ:FOLD) Analyst Rating Consensus - Trade Calls
06/20/16 03:54 PMOverview of Analyst's Recommendations: Mylan N.V. (NASDAQ:MYL) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
06/17/16 03:54 PMAnalyst's Focused Stocks: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
06/15/16 04:06 PMAnalysts Suggestion Alert: Mylan N.V. (NASDAQ:MYL) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
06/14/16 08:53 AMAnalyst Ratings Buzz: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - News Oracle
06/14/16 08:53 AMHC Stocks Outlines: Endologix, Inc. (NASDAQ:ELGX), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - share market updates (press release)
06/14/16 08:53 AMPrice Target Summary Report: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Expedia Inc. (NASDAQ:EXPE) - Beacon Chronicle
06/13/16 01:25 PMAMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vot -
06/11/16 04:09 PMBTIG Research Reaffirms Neutral Rating for Valeant Pharmaceuticals Intl Inc (VRX)
06/10/16 07:21 AMBRIEF-Amicus Therapeutics appoints Craig Wheeler to board of directors - * Amicus therapeutics appoints Craig Wheeler to board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
06/10/16 06:31 AM7:31 am Amicus Therapeutics appoints Craig Wheeler to Board of Directors -
06/10/16 06:30 AMAmicus Therapeutics Appoints Craig A. Wheeler to Board of Directors - [GlobeNewswire] - CRANBURY, N.J., June 10, 2016-- Amicus Therapeutics, a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board ...
06/10/16 05:37 AMMost recent Trading report: Novo Nordisk A/S (NYSE:NVO) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
06/09/16 04:08 PMAMICUS THERAPEUTICS INC Files SEC form 8-K, Financial Statements and Exhibits -
06/09/16 06:16 AMStock's Earnings Analysis: Two Harbors Investment Corp. (NYSE:TWO), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Beacon Chronicle
06/08/16 04:17 PMEarnings in Focus: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Oncothyreon Inc (NASDAQ:ONTY) - Beacon Chronicle
06/07/16 04:13 PMAnalyst Opinions on: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Scorpio Tankers Inc. (NYSE:STNG) - Beacon Chronicle
06/07/16 04:13 PMAnalyst Opinions on: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Scorpio Tankers Inc. (NYSE:STNG) - Beacon Chronicle
06/07/16 09:33 AMAMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/06/16 03:55 PMStocks Analysts Ranking Summary: Johnson & Johnson (NYSE:JNJ) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
06/06/16 03:55 PMStock in Action: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - News Oracle
06/06/16 07:28 AMHC Stocks Newsbeat: Celgene Corporation (NASDAQ:CELG), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - share market updates (press release)
06/04/16 06:22 AMRedmile Group LLC Increased Amicus Therapeutics INC (NASDAQ:FOLD) by $3.50 Million as Shares Declined - CCH Daily News
06/03/16 04:18 PMAnalysts Review of Stocks: Galena Biopharma, Inc. (NASDAQ:GALE) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates
06/03/16 04:18 PMAnalyst Overview on These 2 Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Raytheon Company (NYSE:RTN) - Beacon Chronicle
06/03/16 04:18 PMAMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) FINANCIAL CONDITION REPORT - CML News
06/03/16 06:31 AMGalena Biopharma (NASDAQ:GALE) & Amicus Therapeutics, (NASDAQ:FOLD) Healthcare Stocks Under Consideration - Wall Street 24 - Galena Biopharma (NASDAQ:GALE) & Amicus Therapeutics, (NASDAQ:FOLD) Healthcare Stocks Under ConsiderationWall Street 24On Wednesday, Shares of Galena Biopharma Inc (NASDAQ:GALE) gained 19.34% to $2.16. The share price is trading in a range of $2.04 – $2.29. The stock exchanged hands with 27.80 Million shares contrast to its average daily volume of 1.77 Million ...and more »
06/02/16 04:14 PMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Quarterly EPS Estimate At $-0.33 - Investor Newswire - Amicus Therapeutics, Inc. (NASDAQ:FOLD) Quarterly EPS Estimate At $-0.33Investor NewswireFirst Call stated that Amicus Therapeutics, Inc. (NASDAQ:FOLD) can touch $12.63 in coming one year. For the next quarter, the per-share earnings target is $-0.33 and for ongoing fiscal at $-1.35. EPS target for next year is $-1.06 versus the mean EPS ...and more »
06/02/16 04:14 PMHave a Glance at: Minerva Neurosciences Inc (NASDAQ:NERV), Amicus Therapeutics, Inc. (NASDAQ:FOLD), Celldex ... - The Point Review - The Point ReviewHave a Glance at: Minerva Neurosciences Inc (NASDAQ:NERV), Amicus Therapeutics, Inc. (NASDAQ:FOLD), Celldex ...The Point ReviewShares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) rose 9.68% to $7.88 at 11:49 AM EDT. The stock exchanged hands of 1.29 million shares recently versus average trading capacity of 2.00 million shares. However recently the stock touch highest trading ...Analyst Price Target Recommendation about two Stocks: Shire plc (NASDAQ:SHPG), Minerva Neurosciences, Inc ...WsNews 4investorsall 10 news articles »
06/01/16 04:17 PMAllergan plc Ordinary Shares (NYSE:AGN) & Amicus Therapeutics, Inc. (NASDAQ:FOLD) Healthcare Stocks in Focus - Wall Street 24 - Allergan plc Ordinary Shares (NYSE:AGN) & Amicus Therapeutics, Inc. (NASDAQ:FOLD) Healthcare Stocks in FocusWall Street 24On Tuesday, Shares of Allergan plc Ordinary Shares (NYSE:AGN) gained 0.03% to $236.00. The share price is trading in a range of $234.90 – $242.35. The stock exchanged hands with 7.80 Million shares contrast to its average daily volume of 4.10 Million ...and more »
06/01/16 04:17 PMTwo Stocks within Analysts Review: Baxalta Incorporated (NYSE:BXLT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates - The Point ReviewTwo Stocks within Analysts Review: Baxalta Incorporated (NYSE:BXLT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD)Street UpdatesOn 5/31/2016, Baxalta Incorporated (NYSE:BXLT) ended trading session lower at $45.23 with -0.66%. The company traded a volume of 15.43 million shares as comparison to average volume of 11.06 million shares. During the 52 –week period, the stock's ...Investor's Watch List: MannKind Corporation (NASDAQ:MNKD), Baxalta Inc (NYSE:BXLT), Amicus Therapeutics, Inc ...The Point ReviewTrending Biotech Stocks Update: Baxalta Incorporated (NYSE:BXLT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD)Is storiesall 28 news articles »
06/01/16 04:17 PMMarket Insights on Amicus Therapeutics, Inc. (NASDAQ:FOLD) - The Point Review - The Point ReviewMarket Insights on Amicus Therapeutics, Inc. (NASDAQ:FOLD)The Point ReviewAmicus Therapeutics, Inc. (NASDAQ:FOLD) has grabbed the attention from analysts, when it saw a value increase of 0.28 percent in the last trading session. A total of 3.94 million shares exchanged hands during the intra-day trade compared with its ...Amicus Therapeutics, Inc. (FOLD): European Commission Approves GalafoldBidness ETCHC Stocks Momentum: ChemoCentryx Inc (NASDAQ:CCXI), Amicus Therapeutics, Inc. (NASDAQ:FOLD)share market updates (press release)Amicus Therapeutics, Inc. (FOLD) Stumbles Following Drug ApprovalSchaeffers Research (blog)StreetInsider.com -CWRU Observer -NYSE Journal (press release)all 24 news articles »
06/01/16 04:01 PMAmicus Therapeutics, Inc. :FOLD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
06/01/16 06:30 AMAmicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference - [GlobeNewswire] - CRANBURY, N.J., June 01, 2016-- Amicus Therapeutics, a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive ...
05/31/16 09:53 PMTrending Biotech Stocks Update: Baxalta Incorporated (NYSE:BXLT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Is stories - Is storiesTrending Biotech Stocks Update: Baxalta Incorporated (NYSE:BXLT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD)Is storiesIn most recently trading session on 5/27/2016, Amicus Therapeutics, Inc. (NASDAQ:FOLD) climbed +0.43% while traded on 1.15 million shares versus it's an average volume of 2.52 million shares. The company recorded the last trade with the price of $7.06.and more »
05/31/16 09:53 PMAmicus Therapeutics, Inc. (FOLD): European Commission Approves Galafold - Bidness ETC - Bidness ETCAmicus Therapeutics, Inc. (FOLD): European Commission Approves GalafoldBidness ETCAmicus Therapeutics, Inc. (NASDAQ:FOLD) shares were extremely volatile during the early trading hours today, as the company announced that the European Commission has granted a complete approval for Galafold—an oral small-molecule ...Amicus Therapeutics, Inc. (FOLD) Stumbles Following Drug ApprovalSchaeffers Research (blog)Amicus Therapeutics (FOLD) Granted European Commission Approval for Galafold in Fabry DiseaseStreetInsider.comStock's Buzz on These Trending Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Shire PLC (ADR) (NASDAQ ...The Point ReviewCWRU Observer -GlobeNewswire (press release) -Benzingaall 14 news articles »
05/31/16 04:12 PMAmicus Therapeutics, Inc. (FOLD) Stumbles Following Drug Approval - Schaeffers Research (blog) - Schaeffers Research (blog)Amicus Therapeutics, Inc. (FOLD) Stumbles Following Drug ApprovalSchaeffers Research (blog)It's already been an eventful morning for biotech stocks, and now Amicus Therapeutics, Inc. (NASDAQ:FOLD) is getting in on the action. The stock is fluctuating amid heavy volume -- last seen 1% lower at $6.99 -- on news the drug company's Fabry disease ...Amicus Therapeutics, Inc. (FOLD): European Commission Approves GalafoldBidness ETCAmicus Therapeutics (FOLD) Granted European Commission Approval for Galafold in Fabry DiseaseStreetInsider.comHow high can Amicus Therapeutics, Inc. (NASDAQ:FOLD) stock go' Analysts hold 17.00CWRU ObserverThe Point Review -GlobeNewswire (press release) -Benzingaall 15 news articles »
05/31/16 09:55 AMAmicus Therapeutics Gets European Commission Approval For Galafold in Patients With Fabry Disease -
05/31/16 07:18 AMAmicus' Fabry disease drug gets European Commission approval -
05/28/16 04:33 PMLongwood Capital Partners LLC Increased Amicus Therapeutics INC (NASDAQ:FOLD) by $7.98 Million as Shares ... - CCH Daily News - Longwood Capital Partners LLC Increased Amicus Therapeutics INC (NASDAQ:FOLD) by $7.98 Million as Shares ...CCH Daily NewsLongwood Capital Partners Llc increased its stake in Amicus Therapeutics Inc (NASDAQ:FOLD) by 66.37% based on its latest 2016Q1 regulatory filing with the SEC. Longwood Capital Partners Llc bought 997,339 shares as the company's stock declined ...Acuta Capital Partners buys $15.8 Million stake in Amicus Therapeutics (FOLD)Market DigestIs it Time to Cash in Profits on Amicus Therapeutics, Inc. (NASDAQ:FOLD)Franklin Independentall 3 news articles »
05/27/16 07:32 AMHealthcare Moving Stocks: Abbott Laboratories (NYSE:ABT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Is stories - Is storiesHealthcare Moving Stocks: Abbott Laboratories (NYSE:ABT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD)Is storiesIn most recently trading session on 5/26/2016, Amicus Therapeutics, Inc. (NASDAQ:FOLD) dropped -0.99% while traded on 1.76 million shares versus it's an average volume of 2.52 million shares. The company recorded the last trade with the price of $7.03.Today Analyst Opinions: Abbott Laboratories (NYSE:ABT), Sanofi (NYSE:SNY)WsNews 4investorsall 23 news articles »
05/26/16 07:46 AMEarnings Review and Stock Rundown for Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Wall Street Hints and News - Earnings Review and Stock Rundown for Amicus Therapeutics, Inc. (NASDAQ:FOLD)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Amicus Therapeutics, Inc. (NASDAQ:FOLD ...and more »
05/25/16 09:35 PMAmicus Therapeutics, Inc. (NASDAQ:FOLD) Closes At $7.140 - Investor Newswire - Amicus Therapeutics, Inc. (NASDAQ:FOLD) Closes At $7.140Investor NewswireYesterday, the stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) closed at $7.140 after opening at $7.190 and registering high of $7.250 and low of $7.060. The last price is $-11.695 off 1-year high of $18.830 and $2.145 away from low of $4.990 during ...Amicus Therapeutics, Inc. (NASDAQ:FOLD): Analysts Quick Take on EarningsNews Tribuneall 4 news articles »
05/24/16 04:36 PMHealthcare stocks to Observe: Baxter International Inc. (NYSE:BAX) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Is stories - Healthcare stocks to Observe: Baxter International Inc. (NYSE:BAX) , Amicus Therapeutics, Inc. (NASDAQ:FOLD)Is storiesIn most recently trading session on 5/23/2016, Amicus Therapeutics, Inc. (NASDAQ:FOLD) climbed +1.17% while traded on 1.56 million shares versus it's an average volume of 2.55 million shares. The company recorded the last trade with the price of $6.92.and more »
05/23/16 04:32 PMTop News: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Cartesian, Inc. (NASDAQ:CRTN), Weis Markets, Inc. (NYSE ... - KC Register - Top News: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Cartesian, Inc. (NASDAQ:CRTN), Weis Markets, Inc. (NYSE ...KC RegisterAmicus Therapeutics, Inc. (NASDAQ:FOLD) announced financial results for the first quarter ended March 31, 2016. Total operating expenses in the first quarter of 2016 increased to $43.0 million compared to $24.1 million for the first quarter 2015 ...
About Amicus Therapeutics

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: FOLD
  • CUSIP: 03152W10
Key Metrics:
  • Previous Close: $5.00
  • 50 Day Moving Average: $6.49
  • 200 Day Moving Average: $7.29
  • P/E Ratio: N/A
  • P/E Growth: -0.10
  • Market Cap: $689.88M
  • Current Quarter EPS Consensus Estimate: $-1.35 EPS
Additional Links:
Amicus Therapeutics (NASDAQ:FOLD) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha